Introduction
The peptide therapeutics market is experiencing unprecedented growth. Valued at approximately $44 billion in 2024, the market is projected to surpass $60 billion by 2028, a compound annual growth rate (CAGR) of roughly 9.5%. For researchers, compounding pharmacies, and peptide suppliers, understanding these trends isn't just academic, it directly impacts testing demand, quality expectations, and regulatory scrutiny.
At ACS Peptide Testing Labs, we've seen this surge firsthand. Our sample volume has grown over 40% year-over-year, with GLP-1 agonists alone accounting for nearly a third of all testing requests in early 2026.
What's Driving the Peptide Market Boom?
GLP-1 Agonists Are Reshaping Pharma
The explosive commercial success of semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) has made GLP-1 receptor agonists the fastest-growing drug class globally. Combined revenues for these two molecules exceeded $40 billion in 2025, and demand shows no signs of slowing.
This has created a downstream effect:
- Compounding pharmacies are formulating GLP-1 peptides at scale to address supply shortages
- Research institutions are studying next-generation multi-agonists like retatrutide
- Peptide suppliers are scaling production to meet demand from both research and clinical markets
The Compounding Pharmacy Expansion
FDA guidance on compounding of GLP-1 peptides has opened a significant market for 503A and 503B pharmacies. However, this expansion comes with heightened quality requirements:
- Identity confirmation via mass spectrometry is now expected (not just HPLC purity)
- Endotoxin testing is required for injectable preparations
- State pharmacy boards are increasingly requesting third-party Certificates of Analysis
Obesity and Metabolic Disease Pipeline
Beyond currently approved drugs, the obesity pipeline is packed with peptide-based candidates:
| Peptide | Mechanism | Stage | Developer |
|---|---|---|---|
| Retatrutide | GIP/GLP-1/Glucagon triple agonist | Phase 3 | Eli Lilly |
| Survodutide | Glucagon/GLP-1 dual agonist | Phase 3 | Boehringer Ingelheim |
| Pemvidutide | GLP-1/Glucagon dual agonist | Phase 2 | Altimmune |
| Orforglipron | Oral GLP-1 agonist (non-peptide) | Phase 3 | Eli Lilly |
| CagriSema | Amylin/GLP-1 combination | Phase 3 | Novo Nordisk |
Key Market Segments Driving Testing Demand
1. Research Peptide Suppliers
The research peptide market has grown in parallel with therapeutic development. Suppliers need independent testing to:
- Verify synthesis quality before shipping to customers
- Provide credible Certificates of Analysis
- Differentiate from competitors on quality
Our data shows that supplier verification testing requests have increased 55% since 2024.
2. Compounding Pharmacies
503A and 503B pharmacies represent the fastest-growing segment of our client base. Testing needs include:
- Identity confirmation. Is this actually semaglutide?
- Purity verification. Does it meet USP standards?
- Sterility and endotoxin screening. Is it safe for injection?
- Potency/quantity testing. Does the vial contain the labeled amount?
Read more about testing for compounding pharmacies.
3. Academic and Clinical Researchers
As peptide research funding increases, so does demand for rigorous analytical verification. NIH-funded studies increasingly require independent testing documentation, and journal reviewers are asking for third-party purity data.
